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Objective To evaluate the effect of ritodrine sustained release capsules for maintaining uterine
quiescence after successful treatment of active preterm labour.
Design Multicentre placebo-controlled trial.
Setting Five teaching hospitals in the Netherlands.
Participants Women (n — 95) at less than 35 weeks of gestation in whom active preterm labour had
been stopped with intravenous ritodrine.
Interventions Women received either two 40 mg ritodrine sustained release capsules (n = 50) or
identical placebo capsules (n — 45) three times a day for seven days.
Results The proportion of women who received another course of active treatment was
significantly smaller with the sustained release than with placebo (1 of 50 versus 11 of 45: 
p  =  0-003) as was the number delivering because of preterm labour during treatment (0 of 50 
versus 4 of 45 : P — 0-04). There were no other significant differences between the two groups.
Conclusions Maintenance treatment with ritodrine sustained release capsules after arrest of
preterm labour reduces the risk of recurrences of preterm labour that necessitate treatment or 
precipitate delivery.
INTRODUCTION wished to examine whether the use of this sustained
There is some evidence from controlled studies please preparation would be sufficiently effective
in reducing recurrences of preterm labour to
warrant its use in clinical practice.
inhibition of preterm labour with beta- 
mimetics is more likely to be effective when 
intravenous treatment is followed by oral main­
tenance than when it is not. That evidence is weak, 
however, and spread across three small studies not 
all of which used the same betamimetic agent1 3. 
Among them they only showed fewer relapses and 
longer relapse free intervals, but no reduction in
the incidence of preterm . These not
particularly impressive effects required the fre­
quent intake of a large number of tablets to 
compensate for the low bioavailability and short 
half-lives of oral betamimeticsfl.
The use of ritodrine in a sustained release 
formulation permits the limitation of betamimetic 
intake to three times a day while obtaining plasma 
levels that parallel the lower range of effective 
intravenous treatment7 with few side effects7,8. We
Correspondence: Dr C. A. G. Holleboom, Department of Ob­
stetrics and Gynaecology, Bronovo Hospital, Bronovolaan 5, 
2597 AX The Hague, The Netherlands.
METHODS
A placebo-controlled comparison of ritodrine 
sustained release capsules for maintaining uterine 
quiescence after arrest of preterm labour was
conducted with approval at five Dutch
teaching hospitals. Women recruited for the study 
were those who had participated in a randomized 
comparison of two schedules of intravenous 
ritodrine administration, described elsewhere”, and 
in whom this had resulted in the arrest of active 
preterm labour. Of the 143 women in whom 
preterm labour had been stopped with either one 
of two ritodrine schedules, 18 were not eligible 
because they had received indomethacin (n 
had ruptured membranes (n =  2), had experienced 
severe side effects during intravenous treatment 
(« =  4), or were beyond 34 
{n =  ô)”. Of the 125 women who were eligible, 30
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Table 1. Baseline characteristics o f  women participating in the oral maintenance trial.
Characteristics
Ritodrine
n =  50
Placebo 
;i =  45 P
Age (years) 29-0 (5-2) 28-7 (5*0) 0-801
Duration o f  pregnancy at trial entry (days) 219 (14) 219 (16) 0-841
Multiple pregnancy 0-0062
Twins 7
Triplets 1 * ........."
Tocolytic index (ref. 20) 2-8 (0-9) 3 0 ( H ) 0-57:i
Bishop score 4-0 (1-8) 4'2 (1-7) 0,64:|
Intravenous ritodrine treatment schedule 0-594
prior to trial entry
Loading dose 25 25
Incremental dose 25 20
Total duration (days) 4-1 (3-2) 3 9 (2-2) 0-805
Intravenous treatment until tapering off
Duration (hours) 45 (15) 55 (33) 0-37*
Dose o f  ritodrine (mg) 433 (410) 434 (368) 0-865
Values are n or mean with SD in parentheses.
Statistical tests: 11 test, 2Fisher exact, 8Cochran-Mantel-Haenszel, 4%a test, 6Wilcoxon.
did not participate in the present study: 16 because venous treatment or leading to delivery, or after 
they received active treatment without blinding; seven days. Other tocolytic agents were not used.
eight because of transfer to a nonparticipating The main outcome parameters were admin-
hospital or lack of consent; and six for reasons istration of another course of intravenous tocolysis
that were not documented. Thus, 95 women and delivery during the seven days of maintenance
participated in the trial; 50 of them had originally treatment. Additional predefined outcomes were:
received the loading and 45 the incremental dose number of deliveries before 35 and 37 weeks and
schedule of intravenous treatment9 (Table 1). the presence of side effects irrespective of whether
It had been estimated that with an anticipated or not these prompted arrest of treatment.
> 90 % success rate of the active treatment a Statistical analysis was by x2 test, Fisher’s exact
sample of 100 women would have 80 % power to test for expected numbers below 5, and confidence 
detect a 20% difference in the frequency of interval analysis10. A two-tailed P value <0*05 
successful maintenance between the active treat- was considered to be stastically significant, 
ment and placebo (two-tailed a =  0-05). Success 
was defined as no delivery and no administration 
of a new course of active tocolytic treatment RESULTS
(intravenous tocolysis) during the seven days of Only one of the women (2%) who received
ritodrine-sustained release capsules underwent amaintenance.
At the start of maintenance treatment, all women new intravenous infusion, compared with 10 of 
had been on an intravenous dose of 50 (ig/min those (22-2 %) who received placebo capsules, a
ritodrine for 12 to 24 h following successful arrest difference that is highly significant (%£
of contractions. Maintenance consisted o f  either 
two 40 me ritodrine-sustained release caDSules or
7-6,
p  =  ()•()()6; Table 2), One woman (after loading 
dose allocated to placebo) did not comply with
treatment
methacin. A further placebo-treated woman had a 
recurrence of preterm labour deemed to be beyond 
rescue; she delivered without re-infusion. All but 
sation for the duration of the seven-day main- one of the re-infusions occurred within the first
two identical placebo capsules three times a da> 
for seven days supplied in block-randomised 
pharmacy-coded drug boxes. The protocol recom 
mended bedrest for the first 48 h and hospital!
A new episode of three days of stopping intravenous treatment and
escribed with the same regimen three of the women (all in the placebo group;
that the woman had received previously if active 
labour recurred before 34 weeks of gestation. Main­
tenance treatment was to be stopped in the event 
of severe side effects, intrauterine infection, fetal preterm labour 
distress, recurrent preterm labour reauirine intra-
Table 2) delivered despite re-infusion. There was
;ant difference inalso a statistically 
number of women delivering because of recurrent
treatment (0 versus 4;
Fisher’s exact test, P =  0*04), but not in the total
© R C O G  1996 Br J Ohstei Gvnaecol 103, 702 -705
9-
704 C. A. G. HOLLEBOOM ET AL.
Table 2. Outcome characteristics with the two maintenance treatments
Outcome
Ritodrine 
(n =  50)
Placebo 
(n =  45)
Difference (%) and 
95% confidence interval
New active treatment 1 11 -2 2 -4  ( -3 5 -6  to -9 -3 )
Intravenous ritodrine 1 10* -2 0 -2  ( - 3 3 - 0  to -7 -5 )
Indomethacin 0 It - 2 - 2  ( - 6 - 5  to 2-1)
Delivered
Within 7 days I** 4 - 6 - 9  ( -1 6 -1  to 2-3)
Before 35 weeks 2 6 -9 -3  ( -2 0 -7  to 2 0)
Before 37 weeks 16 13 3-1 ( -1 5 -4  to 21-6)
Discharged from hospital
Within 5 days 10 8 2-2 ( -1 3 -5  to 18-0)
Within 7 days 20 19 - 2 - 2  ( -2 2 -0  to 17-6)
Not before delivery 3 7 - 9 - 6  ( -2 2 -0  to 2-9)
Treatment stopped due to side effects 1 0 2-0 ( - 1 - 9  to 5-9)
Side effects
Headache 1 0 2-0 ( - 1 - 9  to 5-9)
Hypertension 0 1 — 2-2 ( — 6-5 to 2T )
Tremor 2 0 4-0 ( - 1 - 4  to 9-4)
Vomiting 1 0 2-0 ( - 1 - 9  to 5-9)
Neurological problems 0 1 - 2 - 2  ( - 6 - 5  to 2-1)
Fetal and neonatal deaths 1 0 2-0 ( — 1*9 to 5-9)
* Of whom 3 delivered within 7 days and below 34 weeks.
** Caesarean section because o f  vaginal bleeding in the absence o f  contractions, 
f  Lack o f  compliance with maintenance treatment.
number of deliveries during treatment (Table 2). adrenergic receptors to betamimetic agents13. Still 
There were no other statistically significant differ- others reflect concepts, such as down-regulation of
ences between the groups; neither in duration of 6-adrenergic receptors 15, 16 that may limit the
hospitalisation, gestational age at delivery or utility of long-term tocolysis, or beliefs that 
incidence of side effects (Table 2). In only one tocolytic treatments are symptomatic in nature 
woman (in the ritodrine group) treatment was and thence superfluous when symptoms are no 
stopped because of side effects (headache; Table 2). longer present. These many persuasions gain a 
There was one case o f abruption four days after great deal o f impetus from the limited bio­
stopping placebo treatment and one death: an availability of betamimetics after oral adminis- 
unexplained intrauterine death of a mature infant tration and the short half-lives which require 
two months after the end of the trial (ritodrine tablets to be taken at frequent intervals throughout 
group) and a further 27 days of open oral ritodrine the day and night, if pharmacological credibility is 
treatment. Except for this death and one mother to be sustained3,6,8,13. Yet, many clinicians feel 
who could not be traced after moving to another something incongruous in waking a woman, who 
city, all mothers and infants were well at follow up is finally asleep after the uterus has been subdued.
in the postneonatal period.
DISCUSSION
merely to maintain the status quo so that she can 
sleep again.
Oral preparations of ritodrine have a bio-
Although virtually all controlled trials of beta- availability of about 30% 7, 17 ,and they must be
mimetic agents in the treatment of preterm labour taken 6 times a day in order to maintain reasonable 
have incorporated an episode of maintenance plasma levels18. It has been argued that the low 
treatment11,12, there is divergence of opinion efficacy of the medication is often due to in-
between countries and individual obstetricians adequate plasma levels6. With the sustained release
on whether maintenance treatment is worthwhile capsules three doses of 80 mg a day are sufficient
after arrest of active preterm labour13,14. There to obtain plasma levels that are equivalent to
are many reasons for this, not the least of which those obtained with an intravenous infusion of
is lack of evidence that such treatment reduces the 50 |Ag/min ritodrine without serious side effects7,19,
preterm birth rate4,5. Other reasons relate to a The fact that only one of 95 women in our study
wide range of potential, albeit mainly hypothetical failed to comply with the prescribed maintenance
s of prolonged exposure of fetal beta- of three doses a day suggests that this treatment is
© RCOG 1996 Br J Obstet Gvnaecol 103, 702-7051
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much easier to tolerate than the usual schedules 
that require around the clock administration.
Our study now clearly demonstrates that sus­
taining uterine relaxation with this regimen of 
ritodrine maintenance reduces the likelihood that 
women will require another course of intravenous 
treatment. There is now also evidence that this 
treatment is more likely to delay delivery for at 
least seven days than no maintenance treatment.
These conclusions gain further credence from the 
fact that there were significantly more multiple
pregnancies in the ritodrine than in the placebo 10 Gardner MJ, Altman DG. Calculating confidence intervals for
arm of the trial. Both effects can be clinically
5 Cabrol D. The therapeutic value o f prophylactic and maintenance 
treatment in preterm labour, Res Clin Forums 1994; 16: 127-138.
6 Schiff E, Sivan E, Terry S et at. Currently recommended oral 
regimens for ritodrine tocolysis result in extremely low plasma 
levels. Am J  Obstet Gynecol 1993; 169: 1059—1064.
7 Essed GGM, Struyker Boudier HAJ, van Zijl JAWM. Bio- 
pharmaceutical aspects of ritodrine retard in pregnant women. 
Arch Int Pharmacodyn 1988; 293: 295-300.
8 Witter FR, Benedetti TJ, Petty BG, Feldman AM, Traill TA, 
Anderson J. Pharmacodynamics and tolerance of oral sustained 
release ritodrine. Am J  Obstet Gynecol 1988; 159: 690-695.
9 Holleboom CAG, Merkus JMWM, van Eiferen LWM, Keirse 
MJNC. Randomised comparison between a loading and in­
cremental dose model for ritodrine administration in preterm 
labour. Br J Obstet Gvnaecol 1996; 103: 695 701,
proportions and their differences. In: Gardner MJ, Altman DG, 
editors. Statistics with Confidence, London: British Medical 
Journal, 1989: 28-33.worthwhile especially when considered in terms of
the hazards and maternal discomfort arising from 11 King JF, Grant A, Keirse MJNC, Chalmers I. Betamimetic« in
each new course of intravenous betamimetic 
treatment, as well as the cost of re-admission and
hospitalisation of women with recurrent preterm 
labour.
preterm labour: a pooled analysis of the randomised controlled 
trials. Br J  Obstet Gynaecol 1988; 95: 211- 222.
12 Canadian Preterm Labor Investigators Group. Treatment of 
preterm labor with the beta-adrenergic agonist ritodrine. N  Engl 
J  M e d  1992; 327: 308-312.
13 Keirse MJNC. Betamimetic drugs in the prophylaxis of preterm 
labour: extent and rationale of their use. Br J  Obstet Gvnaecol 
1984;91:431-437.
14 Lamont RF. Clinical perspectives on current opinion for treatment 
strategy. Res Clin Forums 1994; 16: 139-154.
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